ArticleWorld journal of surgical oncology2020

Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.

Yuying Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.